NewsSource: EClinCloud

EClinCloud Invites You to the 2023 China (Ningbo) Biopharmaceutical Industry Development Summit

2 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration
Article illustration


From March 10 to 12, 2023, the "2023 China (Ningbo) Biopharmaceutical Industry Development Summit and SAPA-China US-China Global New Drug Innovation and Clinical Development Conference" will be held at Empark Grand Hotel Hangzhou Bay in Qianwan, Ningbo.


In today's challenging domestic and global environment, optimizing global clinical development and cross-border collaboration has become a pressing challenge for pharmaceutical companies. Spanning both China and the United States, the SAPA-China US-China Global New Drug Innovation and Clinical Development Conference connects industry leaders to discuss the challenges, opportunities, and strategies in innovative drug development.


EClinCloud Keynote Presentation


Applying eCOA to Enable Patient-Centered Clinical Research


In Sub-forum 2 on "Real-World Data (RWE)" on the afternoon of March 12, Dr. Qin Long, CEO of EClinCloud, will deliver a keynote presentation titled "Applying eCOA to Enable Patient-Centered Clinical Research" from 15:20 to 15:50. Starting from the concept of COA, the presentation will detail the significance and value of eCOA for "patient-centered" clinical trials and share global regulatory perspectives on the use of eCOA alongside practical case studies. We welcome you to join the discussion and look forward to meeting you in Qianwan, Ningbo, from March 10 to 12.


Article illustration




Article illustration
Article illustration


Article illustration
Article illustration




*Note: For the detailed conference agenda, please follow the "Shengjie Qianyan" (盛杰前沿) WeChat official account.




About EClinCloud

EClinCloud is a technology company dedicated to clinical R&D, providing an integrated, interoperable all-in-one clinical trial cloud platform (including technology products such as CTMS, eTMF, EDC, RTSM, eCOA, and eConsent, as well as solutions such as scale management, linguistic validation, rater training, and data quality analysis) alongside clinical trial endpoint assessment technologies across therapeutic areas (including oncology, central nervous system, and ophthalmology). By combining cutting-edge technology with life sciences data, it builds a globally leading "patient-centered" SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article illustration


Read original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.